Linda Z. Penn

The paper identifies CHD1 as a synthetic lethal target in MYC-driven breast cancer, showing that its loss suppresses tumor growth and induces cell death in MYC-overexpressing models.

The paper determines the structural basis of TMPRSS11D autocleavage activation and shows that nafamostat mesylate is cleaved by TMPRSS11D, reducing its efficacy as a protease inhibitor.

This paper describes a targeted protein degradation strategy using UNC8732 to recruit FBXO22 for NSD2 degradation, leading to growth suppression and reversal of drug resistance in leukemia cells.